FOEHR MATTHEW W 4

4 · OmniAb, Inc. · Filed Feb 18, 2026

AI-generated summary of this filing

Updated Feb 18, 2026

OmniAb (OABI) CEO Matthew W. Foehr Receives RSUs, Sells Shares

What Happened

Matthew W. Foehr, President, CEO and Director of OmniAb (OABI), had derivative awards convert and RSUs granted/vested on Feb 18, 2026 and sold 30,843 shares in an open‑market "sell-to-cover" for $52,742 (weighted avg $1.71).
The filing shows conversion/exercise or similar derivative activity of 58,333 shares, two award/grant entries for 156,250 and 1,562,500 RSU-type units (all recorded at $0.00 as derivative awards), for a total of 1,777,083 shares acquired/awarded on that date. Separately, 58,333 derivative shares are also listed as disposed at $0.00 in the filing.

Key Details

Transaction date: 2026-02-18 (filed same day).
Sale: 30,843 shares sold at a weighted average price of $1.71; total proceeds reported $52,742. Reported per‑share prices in the sale ranged $1.68–$1.73.
Awards/Conversions: 58,333 shares (exercise/conversion), 156,250 RSUs (award), and 1,562,500 RSUs (award) recorded as acquired (all reported at $0.00 as derivative/award entries).
Derivative disposition: 58,333 shares listed as disposed at $0.00 (reported as derivative).
Shares owned after the transaction: not disclosed in the provided filing summary.
Footnotes of note:
- F1/F5: RSU grants vest in substantially equal annual installments (one set beginning Feb 18, 2026; another beginning Feb 18, 2027).
- F2: Each RSU represents the contingent right to one share of common stock.
- F3/F4: The open‑market sale was a mandatory sell‑to‑cover to satisfy tax withholding; sale price shown is a weighted average (range $1.68–$1.73).
- F6: Stock option grant vesting schedule noted (12.5% after 6 months, then monthly thereafter).
Filing timeliness: No late filing was indicated (filed same day as reported transactions).

Context

This activity appears primarily related to awards/derivative conversion and compulsory tax‑covering sales, not discretionary open‑market selling: the filing documents mandatory sell‑to‑cover to satisfy withholding obligations (per footnote).
For derivative items: a conversion/exercise entry and zero‑proceeds derivative disposition are shown; those entries are recorded as derivative transactions in the Form 4 and may reflect internal settling/withholding mechanics rather than voluntary cash sales.

Form 4

Period: 2026-02-18

DirectorPresident and CEO

Transactions

Exercise/Conversion
Common Stock
[F1][F2]
2026-02-18+58,333→ 4,434,120 total
Sale
Common Stock
[F3][F4]
2026-02-18$1.71/sh−30,843$52,742→ 4,403,277 total
Exercise/Conversion
Restricted Stock Units
[F2][F1]
2026-02-18−58,333→ 189,585 total
→ Common Stock (58,333 underlying)
Award
Restricted Stock Units
[F2][F5]
2026-02-18+156,250→ 345,835 total
→ Common Stock (156,250 underlying)
Award
Stock Option
[F6]
2026-02-18+1,562,500→ 1,562,500 total
Exercise: $1.71Exp: 2036-02-18→ Common Stock (1,562,500 underlying)

Footnotes (6)

[F1]Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on February 18, 2026.
[F2]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
[F3]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.68 to $1.73. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F5]The RSU grant vests in three substantially equal annual installments beginning on February 18, 2027.
[F6]The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter.

Signature

By: /s/ Charles S. Berkman, Attorney-in-Fact for Matthew W. Foehr|2026-02-18

1 file